Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F11%3A11008" target="_blank" >RIV/00216208:11110/11:11008 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/11:00055271 RIV/00216208:11120/11:00003391 RIV/00216208:11150/11:10107683 RIV/65269705:_____/11:#0001454 a 4 dalších

Výsledek na webu

<a href="http://informahealthcare.com/doi/abs/10.3109/10428194.2011.573889" target="_blank" >http://informahealthcare.com/doi/abs/10.3109/10428194.2011.573889</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma

Popis výsledku v původním jazyce

This retrospective study evaluated the secondary clinical risk score at relapse, the prognostic significance of pre-transplant positron emission tomography (PET), and complete remission (CR) assessed by computed tomography (CT) after salvage chemotherapybefore autologous stem cell transplant (ASCT) in 76 patients with relapsed/refractory Hodgkin lymphoma (HL). Median follow-up after ASCT was 23 months. Overall 11/20 PET-positive and 14/56 PET-negative patients relapsed after ASCT. In univariate analysis, only PET negativity before ASCT was significantly associated with better 2-year progression-free survival (PFS) (72.7 +/- 6.3% vs. 36.1 +/- 11.6%, p = 0.01) and 2-year overall survival (OS) (90.3 +/- 4.1% vs. 61.4 +/- 11.6%, p = 0.009). Other factorswere not significant. In multivariate analysis, none of the evaluated factors were significant for PFS and OS. However, positive pre-transplant PET identified a population with worse PFS and OS at least in univariate analysis.

Název v anglickém jazyce

Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma

Popis výsledku anglicky

This retrospective study evaluated the secondary clinical risk score at relapse, the prognostic significance of pre-transplant positron emission tomography (PET), and complete remission (CR) assessed by computed tomography (CT) after salvage chemotherapybefore autologous stem cell transplant (ASCT) in 76 patients with relapsed/refractory Hodgkin lymphoma (HL). Median follow-up after ASCT was 23 months. Overall 11/20 PET-positive and 14/56 PET-negative patients relapsed after ASCT. In univariate analysis, only PET negativity before ASCT was significantly associated with better 2-year progression-free survival (PFS) (72.7 +/- 6.3% vs. 36.1 +/- 11.6%, p = 0.01) and 2-year overall survival (OS) (90.3 +/- 4.1% vs. 61.4 +/- 11.6%, p = 0.009). Other factorswere not significant. In multivariate analysis, none of the evaluated factors were significant for PFS and OS. However, positive pre-transplant PET identified a population with worse PFS and OS at least in univariate analysis.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2011

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Leukemia & Lymphoma

ISSN

1042-8194

e-ISSN

—

Svazek periodika

52

Číslo periodika v rámci svazku

9

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

7

Strana od-do

1668-1674

Kód UT WoS článku

000294228100010

EID výsledku v databázi Scopus

—